• Something wrong with this record ?

The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1

B. Luef, F. Handle, G. Kharaishvili, M. Hager, J. Rainer, G. Janetschek, S. Hruby, C. Englberger, J. Bouchal, FR. Santer, Z. Culig,

. 2016 ; 23 (6) : 495-508. [pub] 20160602

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18011183

Grant support
NV15-28628A MZ0 CEP Register

Due to the urgent need for new prostate cancer (PCa) therapies, the role of androgen receptor (AR)-interacting proteins should be investigated. In this study we aimed to address whether the AR coactivator nuclear receptor coactivator 1 (NCOA1) is involved in PCa progression. Therefore, we tested the effect of long-term NCOA1 knockdown on processes relevant to metastasis formation. [(3)H]-thymidine incorporation assays revealed a reduced proliferation rate in AR-positive MDA PCa 2b and LNCaP cells upon knockdown of NCOA1, whereas AR-negative PC3 cells were not affected. Furthermore, Boyden chamber assays showed a strong decrease in migration and invasion upon NCOA1 knockdown, independently of the cell line's AR status. In order to understand the mechanistic reasons for these changes, transcriptome analysis using cDNA microarrays was performed. Protein kinase D1 (PRKD1) was found to be prominently up-regulated by NCOA1 knockdown in MDA PCa 2b, but not in PC3 cells. Inhibition of PRKD1 reverted the reduced migratory potential caused by NCOA1 knockdown. Furthermore, PRKD1 was negatively regulated by AR. Immunohistochemical staining of PCa patient samples revealed a strong increase in NCOA1 expression in primary tumors compared with normal prostate tissue, while no final conclusion could be drawn for PRKD1 expression in tumor specimens. Thus, our findings directly associate the AR/NCOA1 complex with PRKD1 regulation and cellular migration and support the concept of therapeutic inhibition of NCOA1 in PCa.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011183
003      
CZ-PrNML
005      
20180418125827.0
007      
ta
008      
180404s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1530/ERC-16-0160 $2 doi
035    __
$a (PubMed)27255895
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Luef, Birgit $u Division of Experimental UrologyDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria.
245    14
$a The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1 / $c B. Luef, F. Handle, G. Kharaishvili, M. Hager, J. Rainer, G. Janetschek, S. Hruby, C. Englberger, J. Bouchal, FR. Santer, Z. Culig,
520    9_
$a Due to the urgent need for new prostate cancer (PCa) therapies, the role of androgen receptor (AR)-interacting proteins should be investigated. In this study we aimed to address whether the AR coactivator nuclear receptor coactivator 1 (NCOA1) is involved in PCa progression. Therefore, we tested the effect of long-term NCOA1 knockdown on processes relevant to metastasis formation. [(3)H]-thymidine incorporation assays revealed a reduced proliferation rate in AR-positive MDA PCa 2b and LNCaP cells upon knockdown of NCOA1, whereas AR-negative PC3 cells were not affected. Furthermore, Boyden chamber assays showed a strong decrease in migration and invasion upon NCOA1 knockdown, independently of the cell line's AR status. In order to understand the mechanistic reasons for these changes, transcriptome analysis using cDNA microarrays was performed. Protein kinase D1 (PRKD1) was found to be prominently up-regulated by NCOA1 knockdown in MDA PCa 2b, but not in PC3 cells. Inhibition of PRKD1 reverted the reduced migratory potential caused by NCOA1 knockdown. Furthermore, PRKD1 was negatively regulated by AR. Immunohistochemical staining of PCa patient samples revealed a strong increase in NCOA1 expression in primary tumors compared with normal prostate tissue, while no final conclusion could be drawn for PRKD1 expression in tumor specimens. Thus, our findings directly associate the AR/NCOA1 complex with PRKD1 regulation and cellular migration and support the concept of therapeutic inhibition of NCOA1 in PCa.
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a pohyb buněk $7 D002465
650    _2
$a proliferace buněk $7 D049109
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a koaktivátor 1 jaderných receptorů $x antagonisté a inhibitory $x genetika $x metabolismus $7 D056920
650    _2
$a nádory prostaty $x genetika $x metabolismus $x patologie $7 D011471
650    _2
$a proteinkinasa C $x genetika $x metabolismus $7 D011493
650    _2
$a RNA interference $7 D034622
650    _2
$a androgenní receptory $x genetika $x metabolismus $7 D011944
655    _2
$a časopisecké články $7 D016428
700    1_
$a Handle, Florian $u Division of Experimental UrologyDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria.
700    1_
$a Kharaishvili, Gvantsa $u Department of Clinical and Molecular Pathology and Institute of Molecular and Translational MedicineFaculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Hager, Martina $u Department of PathologyParacelsus Medical University, Salzburg, Austria.
700    1_
$a Rainer, Johannes $u Division of Molecular PathophysiologyBiocenter, Medical University of Innsbruck, Innsbruck, Austria.
700    1_
$a Janetschek, Günter $u Department of UrologyParacelsus Medical University, Salzburg, Austria.
700    1_
$a Hruby, Stephan $u Department of UrologyParacelsus Medical University, Salzburg, Austria.
700    1_
$a Englberger, Christine $u Department of UrologyParacelsus Medical University, Salzburg, Austria.
700    1_
$a Bouchal, Jan $u Department of Clinical and Molecular Pathology and Institute of Molecular and Translational MedicineFaculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Santer, Frédéric R $u Division of Experimental UrologyDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria zoran.culig@i-med.ac.at frederic.santer@i-med.ac.at.
700    1_
$a Culig, Zoran $u Division of Experimental UrologyDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria zoran.culig@i-med.ac.at frederic.santer@i-med.ac.at.
773    0_
$w MED00001521 $t Endocrine-related cancer $x 1479-6821 $g Roč. 23, č. 6 (2016), s. 495-508
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27255895 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180418125927 $b ABA008
999    __
$a ok $b bmc $g 1288668 $s 1007995
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 23 $c 6 $d 495-508 $e 20160602 $i 1479-6821 $m Endocrine-related cancer $n Endocr Relat Cancer $x MED00001521
GRA    __
$a NV15-28628A $p MZ0
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options